During this 90-minute discussion presented by the Life Sciences Foundation and MassBio, a panel of biotech leaders will discuss how patient advocacy has played a pivotal role in shaping the biotech industry and how it informs and adds value to new therapies in development today.

Moderated by Genzyme CEO David Meeker, panelists John Maraganore, Bill Haseltine, and Joan Finnegan Brooks who have each played roles in shaping the history of  advocacy will share examples from the AIDS, cystic fibrosis and rare disease communities.

A few decades ago, patients depended solely on medical providers for disease information, and they were often considered a nuisance by drug developers. Today, health and research information is broadly available and patient groups oftentimes collaborate with biotech companies and raise funds for research.

Yet, patient protests still take place in response to high costs and limited access to certain medicines. This discussion will explore what the biotech industry can learn from the history and evolution of patient advocacy.


Date: Tuesday, April 15

Time: 5:30 – 7:00 pm discussion, introduction by Henri Termeer, 7:00 – 8:00 p.m. reception

Location: Le Meridien Cambridge, 20 Sidney Street, Cambridge, MA, 02139

MassBio Member Fee: $25

General Admission Fee: $35

For more information and to register, visit lifesciencesfoundation.org/voicescarry


Screen Shot 2014-04-07 at 9.35.25 AM